/Company Directory

/

Asset Brief

CACIPLIQ20 (RGTA)

TRP·Tissue Repair·Diabetic foot ulcers (chronic wounds of the leg or foot)·Phase 2·NCT05170984·Primary completion: 1 July 2024

Plain-language Brief

The trial in plain terms

The disease: Diabetic foot ulcers are open sores or wounds on the feet of people with diabetes that fail to heal within an expected timeframe. They are classified as chronic wounds when they persist despite standard care, and they carry a substantial risk of infection and amputation. The global prevalence of diabetes means the population of patients affected by this complication is large, and existing standard-of-care options leave a meaningful proportion of ulcers unhealed (per published estimates in the wound care literature). Treatment options approved specifically for chronic diabetic foot ulcers remain limited.
What the asset is trying to do: CACIPLIQ20 contains an RGTA (ReGeneraTing Agent), which is a synthetic molecule designed to mimic heparan sulfate, a naturally occurring sugar chain found in the tissue matrix that supports wound healing. Heparan sulfate normally binds and protects growth factors that orchestrate tissue repair; in chronic wounds this matrix is degraded and growth factor activity is reduced. By mimicking heparan sulfate, CACIPLIQ20 is intended to restore the local environment needed for healing, an approach that differs from delivering exogenous growth factors directly or from cell-based therapies.
What the trial is measuring, and why it matters: The MATCHOW study (NCT05170984) was a prospective cohort study enrolling patients with hard-to-heal chronic ulcers of the leg or foot, including diabetic foot ulcers, arterial ulcers, and venous ulcers (per ClinicalTrials.gov NCT05170984). The study targeted 191 participants and had a primary completion date of July 2024 (per ClinicalTrials.gov NCT05170984). .
Efficacy benchmarks in this setting: In the diabetic foot ulcer setting, approved comparators and standard wound-care regimens provide a reference point for healing outcomes. Becaplermin gel (PDGF-BB), one of the few agents with a specific regulatory approval in diabetic foot ulcers, demonstrated a complete ulcer closure rate of approximately 50% versus approximately 35% for placebo gel in its pivotal trial (per Wieman et al, Diabetes Care 1998). Bilayered cellular constructs such as Apligraf have shown complete wound closure in a proportion of patients in randomised trials, with figures varying by study (per Veves et al, Diabetes Care 2001). Early-stage or observational data from this asset are not statistically comparable to those pivotal trial results because study designs, patient populations, and follow-up durations differ.
Commercial context: No product in the RGTA class is currently approved by the US FDA or EMA specifically for diabetic foot ulcers, based on publicly available regulatory agency approval lists. CACIPLIQ20 has been studied across several wound types, including post-surgical scars (NCT05528328) and epidermolysis bullosa (NCT06007235), indicating it is not positioned solely in diabetic foot ulcers. Tissue Repair (ASX: TRP) has not disclosed any licensing or partnership deals for CACIPLIQ20 in publicly available ASX announcements reviewed here. .

Sources for this brief (6)

MATCHOW study registry entry: MAtrix Therapy for Hard-to-heal ChrOnic Wounds · ClinicalTrials.gov · accessed 26 June 2026
CACIPLIQ20 Post-surgical Scars Trial · ClinicalTrials.gov · accessed 26 June 2026
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa · ClinicalTrials.gov · accessed 26 June 2026
Becaplermin pivotal trial: Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers · Diabetes Care · accessed 26 June 2026
Graftskin (Apligraf) pivotal trial: Randomised trial of an artificial skin substitute for chronic venous leg ulcers in diabetic patients · Diabetes Care · accessed 26 June 2026
Tissue Repair ASX announcements page · ASX · accessed 26 June 2026

Trial Design

Design summary

Phase: Phase 2
Design type: Prospective cohort study, open-label, single-arm (per ClinicalTrials.gov NCT05170984).
Primary endpoint: [ TODO: fill in from trial protocol or registry — not specified in available data ]
Key secondary endpoints: [ TODO: fill in from trial protocol or registry ]
Enrolment target: 191 patients (per ClinicalTrials.gov NCT05170984)
Current enrolment status: Completed, with primary completion recorded as July 2024 (per ClinicalTrials.gov NCT05170984). Results not reported in available data.
Sites: [ TODO: fill in — site locations not specified in available data ]
Expected readout window: Primary completion was July 2024 per ClinicalTrials.gov NCT05170984; trial status is listed as completed. No results posting or ASX announcement describing data readout has been identified in the announcements provided.

Class Catalyst Calendar

What's landed, what's next for CACIPLIQ20 (RGTA) and peers

CACIPLIQ20 (RGTA)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for CACIPLIQ20 (RGTA). Showing past 6 months and next 12 months · 5 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
BioXTek·Other·Phase 4·NCT07326553
July 2026CT.gov proxy
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
Royal Biologics·Other·Phase 4·NCT07209475
Aug 2026CT.gov proxy
Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs
Assistance Publique Hopitaux De Marseille·Other·Phase 2·NCT02866565
Sept 2026CT.gov proxy
ConferenceESMO Congress 2026· MadridSept 2026
ConferenceSITC Annual Meeting 2026· PhoenixNov 2026
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
Nicolò Brembilla·Other·PHASE1/PHASE2·NCT07048054
Dec 2026CT.gov proxy
ConferenceASH Annual Meeting 2026· New OrleansDec 2026
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
BioLab Holdings·Other·Phase 4·NCT07364630
Jan 2027CT.gov proxy
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
HealthTech Wound Care·Other·Phase 4·NCT07172893
Feb 2027CT.gov proxy
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)
Medical University of Warsaw·Other·Phase 2·NCT06843122
Feb 2027CT.gov proxy
The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial
JSC NextGen·Other·Phase 3·NCT07391319
Mar 2027CT.gov proxy
ConferenceAACR Annual Meeting 2027· OrlandoApr 2027
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.·Other·Phase 2·NCT06189638
Apr 2027CT.gov proxy
ConferenceASCO Annual Meeting 2027· ChicagoJune 2027
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
BioLab Holdings·Other·Phase 4·NCT07089602
July 2027CT.gov proxy
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
Sequence LifeScience, Inc.·Other·Phase 4·NCT07086443
July 2027CT.gov proxy

"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.

Trial design comparison

How CACIPLIQ20 (RGTA) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
CACIPLIQ20 (RGTA)	Tissue Repair	Regenerative Biologic	Phase 2[ TODO: fill in ]	Prospective cohort study, open-label, single-arm (per ClinicalTrials.gov NCT05170984).	[ TODO: fill in from trial protocol or registry — not specified in available data ]	[ TODO: fill in ]	191 patients (per ClinicalTrials.gov NCT05170984)	191
Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 2 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Mesenchymal Stem CellAllo MSC	Off-the-shelf	Batch (donor)	Ryoncil (GvHD only)	Transient	Low
Fc Fusion ProteinFc-fusion trap	Off-the-shelf	Biologic	Eylea / Vabysmo class	Dosing-interval driven	High (incumbents)

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for CACIPLIQ20 (RGTA) yet. Broker coverage of Tissue Repair is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Class Catalyst Calendar

What's landed, what's next for CACIPLIQ20 (RGTA) and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
BioXTek·Other·Phase 4·NCT07326553
July 2026CT.gov proxy
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
Royal Biologics·Other·Phase 4·NCT07209475
Aug 2026CT.gov proxy
Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs
Assistance Publique Hopitaux De Marseille·Other·Phase 2·NCT02866565
Sept 2026CT.gov proxy
ConferenceESMO Congress 2026· MadridSept 2026
ConferenceSITC Annual Meeting 2026· PhoenixNov 2026
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
Nicolò Brembilla·Other·PHASE1/PHASE2·NCT07048054
Dec 2026CT.gov proxy
ConferenceASH Annual Meeting 2026· New OrleansDec 2026
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
BioLab Holdings·Other·Phase 4·NCT07364630
Jan 2027CT.gov proxy
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
HealthTech Wound Care·Other·Phase 4·NCT07172893
Feb 2027CT.gov proxy
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)
Medical University of Warsaw·Other·Phase 2·NCT06843122
Feb 2027CT.gov proxy
The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial
JSC NextGen·Other·Phase 3·NCT07391319
Mar 2027CT.gov proxy
ConferenceAACR Annual Meeting 2027· OrlandoApr 2027
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.·Other·Phase 2·NCT06189638
Apr 2027CT.gov proxy
ConferenceASCO Annual Meeting 2027· ChicagoJune 2027
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
BioLab Holdings·Other·Phase 4·NCT07089602
July 2027CT.gov proxy
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
Sequence LifeScience, Inc.·Other·Phase 4·NCT07086443
July 2027CT.gov proxy

Trial design comparison

How CACIPLIQ20 (RGTA) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
CACIPLIQ20 (RGTA)	Tissue Repair	Regenerative Biologic	Phase 2[ TODO: fill in ]	Prospective cohort study, open-label, single-arm (per ClinicalTrials.gov NCT05170984).	[ TODO: fill in from trial protocol or registry — not specified in available data ]	[ TODO: fill in ]	191 patients (per ClinicalTrials.gov NCT05170984)	191
Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 2 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Mesenchymal Stem CellAllo MSC	Off-the-shelf	Batch (donor)	Ryoncil (GvHD only)	Transient	Low
Fc Fusion ProteinFc-fusion trap	Off-the-shelf	Biologic	Eylea / Vabysmo class	Dosing-interval driven	High (incumbents)

CACIPLIQ20 (RGTA)n = 191

Tissue Repair·Regenerative Biologic·Phase 2·[ TODO: fill in ]

Design: Prospective cohort study, open-label, single-arm (per ClinicalTrials.gov NCT05170984).
Primary endpoint: [ TODO: fill in from trial protocol or registry — not specified in available data ]
Dosing: [ TODO: fill in ]
Eligibility: 191 patients (per ClinicalTrials.gov NCT05170984)

Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Footn = —

Peking University Third Hospital·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?n = —

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcersn = —

Cellution Biologics·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcern = —

Peking University Third Hospital·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trialn = —

Başakşehir Çam & Sakura City Hospital·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Diseasen = —

Biotechnology Institute IMASD·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)n = —

Cellution Biologics·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healingn = —

BioXTek·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.n = —

Royal Biologics·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.n = —

BioLab Holdings·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TLn = —

HealthTech Wound Care·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcersn = —

BioLab Holdings·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapyn = —

Sequence LifeScience, Inc.·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcersn = —

Applied Biologics, LLC·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.n = —

Tiger Biosciences, LLC.·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcersn = —

Dr Azita Hekmatdoost·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcern = —

Energenesis Biomedical Co., Ltd.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)n = —

PolarityTE·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trialn = —

JSC NextGen·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Phase IIb and III Safety and Efficacy Study Chlorin E6 Gel Photodynamic Therapy for Diabetic Foot Ulcers:n = —

United Medical and Dental College·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Woundsn = —

Bardia Anvar·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patientsn = —

Ole Lander Svendsen·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcersn = —

Oneness Biotech Co., Ltd.·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcersn = —

Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcersn = —

Karolinska University Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Smart Boot Use to Measure Offloading Adherencen = —

University of Southern California·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.n = —

Estar Medical dba Medical Technologies, LTD·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nu-3 Gel for Infected Diabetic Foot Ulcersn = —

Lakewood-Amedex Inc·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERsn = —

Assistance Publique Hopitaux De Marseille·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)n = —

Medical University of Warsaw·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcersn = —

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcersn = —

Blue Blood Biotech Corp.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemian = —

MultiGene Vascular Systems Ltd.·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Caren = —

FibroBiologics·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcersn = —

Eluciderm Inc·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcersn = —

Nicolò Brembilla·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureusn = —

Centre Hospitalier Universitaire de Nīmes·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Stem Cell Derived Exome for Treatment of Diabetic Footn = —

Second Affiliated Hospital of Guangzhou Medical University·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Wound Healing Endpoint and Recurrencen = —

Sashwati Roy·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

PU
Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot
Phase 4
Peking University Third Hospital·Recruiting·Primary completion 31 Dec 2024·NCT06062576
AM
Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
Phase 4
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Active, not recruiting·Primary completion 1 May 2025·NCT05804097
CB
Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers
Phase 4
Cellution Biologics·Active, not recruiting·Primary completion 31 Oct 2025·NCT06562296
4 sites
292 enrolled
PU
Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer
Phase 4
Peking University Third Hospital·Recruiting·Primary completion 31 Dec 2025·NCT06197412
BÇ
Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trial
Phase 4
Başakşehir Çam & Sakura City Hospital·Recruiting·Primary completion 4 May 2026·NCT07338773
BI
Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
Phase 4
Biotechnology Institute IMASD·Recruiting·Primary completion 30 May 2026·NCT06952998
CB
Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)
Phase 4
Cellution Biologics·Recruiting·Primary completion 30 June 2026·NCT07014176
B
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
Phase 4
BioXTek·Recruiting·Primary completion 31 July 2026·NCT07326553
RB
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
Phase 4
Royal Biologics·Recruiting·Primary completion 14 Aug 2026·NCT07209475
BH
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
Phase 4
BioLab Holdings·Recruiting·Primary completion 1 Jan 2027·NCT07364630
HW
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
Phase 4
HealthTech Wound Care·Recruiting·Primary completion 21 Feb 2027·NCT07172893
BH
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
Phase 4
BioLab Holdings·Recruiting·Primary completion 1 July 2027·NCT07089602
SL
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
Phase 4
Sequence LifeScience, Inc.·Recruiting·Primary completion 1 July 2027·NCT07086443
AB
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers
Phase 4
Applied Biologics, LLC·Recruiting·Primary completion 1 Aug 2027·NCT07159282
TB
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.
Phase 4
Tiger Biosciences, LLC.·Recruiting·Primary completion 1 Dec 2027·NCT06826339
DA
The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers
Phase 3
Dr Azita Hekmatdoost·Not yet recruiting·Primary completion 1 Aug 2025·NCT06786403
EB
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
Phase 3
Energenesis Biomedical Co., Ltd.·Recruiting·Primary completion 30 Dec 2025·NCT05930210
P
SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)
Phase 3
PolarityTE·Active, not recruiting·Primary completion 31 Dec 2025·NCT06140303
JN
The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial
Phase 3
JSC NextGen·Recruiting·Primary completion 31 Mar 2027·NCT07391319
1 site
UA
Phase IIb and III Safety and Efficacy Study Chlorin E6 Gel Photodynamic Therapy for Diabetic Foot Ulcers:
Phase 3
United Medical and Dental College·Recruiting·Primary completion 1 Sept 2027·NCT07488247
BA
Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
Phase 3
Bardia Anvar·Not yet recruiting·Primary completion 1 Jan 2028·NCT07223892
OL
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
Phase 3
Ole Lander Svendsen·Recruiting·Primary completion 1 Dec 2028·NCT07581145
OB
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
PHASE2/PHASE3
Oneness Biotech Co., Ltd.·Active, not recruiting·Primary completion 8 May 2026·NCT06531512
ZR
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
Phase 2
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.·Recruiting·Primary completion 1 Dec 2025·NCT06852976
KU
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers
Phase 2
Karolinska University Hospital·Not yet recruiting·Primary completion 31 Dec 2025·NCT03137966
UO
Smart Boot Use to Measure Offloading Adherence
Phase 2
University of Southern California·Recruiting·Primary completion 31 Mar 2026·NCT04460573
ED
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
Phase 2
Estar Medical dba Medical Technologies, LTD·Recruiting·Primary completion 15 May 2026·NCT06810726
LI
Nu-3 Gel for Infected Diabetic Foot Ulcers
Phase 2
Lakewood-Amedex Inc·Not yet recruiting·Primary completion 1 June 2026·NCT06020235
AP
Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs
Phase 2
Assistance Publique Hopitaux De Marseille·Not yet recruiting·Primary completion 1 Sept 2026·NCT02866565
UO
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)
Phase 2
Medical University of Warsaw·Not yet recruiting·Primary completion 28 Feb 2027·NCT06843122
JP
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Phase 2
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.·Active, not recruiting·Primary completion 30 Apr 2027·NCT06189638
BB
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Phase 2
Blue Blood Biotech Corp.·Recruiting·Primary completion 31 Dec 2027·NCT06383013
MV
Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
PHASE1/PHASE2
MultiGene Vascular Systems Ltd.·Active, not recruiting·Primary completion 1 Aug 2011·NCT00956332
F
Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care
PHASE1/PHASE2
FibroBiologics·Not yet recruiting·Primary completion 1 Mar 2026·NCT07096934
EI
Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers
PHASE1/PHASE2
Eluciderm Inc·Recruiting·Primary completion 1 June 2026·NCT07396376
NB
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
PHASE1/PHASE2
Nicolò Brembilla·Recruiting·Primary completion 1 Dec 2026·NCT07048054
CH
Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus
PHASE1/PHASE2
Centre Hospitalier Universitaire de Nīmes·Not yet recruiting·Primary completion 1 Nov 2028·NCT02664740
SA
Stem Cell Derived Exome for Treatment of Diabetic Foot
PHASE1/PHASE2
Second Affiliated Hospital of Guangzhou Medical University·Not yet recruiting·Primary completion 30 Dec 2028·NCT06480123
SR
Wound Healing Endpoint and Recurrence
PHASE1/PHASE2
Sashwati Roy·Active, not recruiting·Primary completion 1 Feb 2029·NCT02577120